Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-1002 in NYHA Class III Heart Failure
NCT04179643Phase 1Completed
- Sponsor
- AskBio
- Start
- Nov 2019
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of umiposgene parvec in heart failure (HF) (3 arms), sponsored by AskBio. Primary endpoints: Peak Oxygen Uptake at 12 months and Left Ventricular Ejection Fraction at 12 months. Started Nov 2019; status: completed.
02
Drugs
umiposgene parvec
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04179643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179643.